Filing Details

Accession Number:
0001181431-14-038230
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-12-05 18:40:21
Reporting Period:
2014-12-03
Filing Date:
2014-12-05
Accepted Time:
2014-12-05 18:40:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1407038 Bg Medicine Inc. BGMD In Vitro & In Vivo Diagnostic Substances (2835) 043506204
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1097546 Newcogen Equity Investors Llc C/O Flagship Ventures
One Memorial Drive, 7Th Floor
Cambridge MA 02142
No No Yes No
1222012 Noubar Afeyan C/O Flagship Ventures
One Memorial Drive, 7Th Floor
Cambridge MA 02142
Yes No Yes No
1255927 Jr M Edwin Kania C/O Flagship Ventures
One Memorial Drive, 7Th Floor
Cambridge MA 02142
No No Yes No
1400240 Flagship Ventures Management, Inc. C/O Flagship Ventures
One Memorial Drive, 7Th Floor
Cambridge MA 02142
No No Yes No
1400241 Newcogen Group, Inc. C/O Flagship Ventures
One Memorial Drive, 7Th Floor
Cambridge MA 02142
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-12-03 12,021 $0.04 663,581 No 4 X Indirect Held by NewcoGen Equity Investors LLC
Common Stock Disposition 2014-12-03 927 $0.46 662,654 No 4 S Indirect Held by NewcoGen Equity Investors LLC
Common Stock Acquisiton 2014-12-03 5,988 $0.02 668,642 No 4 X Indirect Held by NewcoGen Equity Investors LLC
Common Stock Disposition 2014-12-03 216 $0.46 668,426 No 4 S Indirect Held by NewcoGen Equity Investors LLC
Common Stock Acquisiton 2014-12-03 12,183 $0.02 680,609 No 4 X Indirect Held by NewcoGen Equity Investors LLC
Common Stock Disposition 2014-12-03 440 $0.46 680,169 No 4 S Indirect Held by NewcoGen Equity Investors LLC
Common Stock Acquisiton 2014-12-03 12,183 $0.02 692,352 No 4 X Indirect Held by NewcoGen Equity Investors LLC
Common Stock Disposition 2014-12-03 440 $0.46 691,912 No 4 S Indirect Held by NewcoGen Equity Investors LLC
Common Stock Acquisiton 2014-12-03 12,183 $0.02 704,095 No 4 X Indirect Held by NewcoGen Equity Investors LLC
Common Stock Disposition 2014-12-03 440 $0.46 703,655 No 4 S Indirect Held by NewcoGen Equity Investors LLC
Common Stock Disposition 2014-12-04 703,655 $0.00 0 No 4 J Indirect Held by NewcoGen Equity Investors LLC
Common Stock Acquisiton 2014-12-04 11,190 $0.00 0 No 4 J Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 X Indirect Held by NewcoGen Equity Investors LLC
No 4 S Indirect Held by NewcoGen Equity Investors LLC
No 4 X Indirect Held by NewcoGen Equity Investors LLC
No 4 S Indirect Held by NewcoGen Equity Investors LLC
No 4 X Indirect Held by NewcoGen Equity Investors LLC
No 4 S Indirect Held by NewcoGen Equity Investors LLC
No 4 X Indirect Held by NewcoGen Equity Investors LLC
No 4 S Indirect Held by NewcoGen Equity Investors LLC
No 4 X Indirect Held by NewcoGen Equity Investors LLC
No 4 S Indirect Held by NewcoGen Equity Investors LLC
No 4 J Indirect Held by NewcoGen Equity Investors LLC
No 4 J Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Warrant to Purchase Common Stock (right to buy) Disposition 2014-12-03 12,021 $0.00 12,021 $0.04
Common Stock Warrant to Purchase Common Stock (right to buy) Disposition 2014-12-03 5,988 $0.00 5,988 $0.02
Common Stock Warrant to Purchase Common Stock (right to buy) Disposition 2014-12-03 12,183 $0.00 12,183 $0.02
Common Stock Warrant to Purchase Common Stock (right to buy) Disposition 2014-12-03 12,183 $0.00 12,183 $0.02
Common Stock Warrant to Purchase Common Stock (right to buy) Disposition 2014-12-03 12,183 $0.00 12,183 $0.02
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2016-07-10 No 4 X Indirect
0 2018-03-28 No 4 X Indirect
0 2020-03-30 No 4 X Indirect
0 2020-09-27 No 4 X Indirect
0 2020-11-04 No 4 X Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 2,434,800 Indirect Held by NewcoGen Group LLC
Common Stock 215,013 Indirect Held by AGTC Advisors Fund, L.P.
Common Stock 2,851,447 Indirect Held by Applied Genomic Technology Capital Fund, L.P.
Common Stock 1,764,286 Indirect Held by Flagship Ventures Fund 2007, L.P.
Footnotes
  1. NewcoGen Group, Inc. ("NG") is the manager of each of NewcoGen Group LLC ("NGG") and NewcoGen Equity Investors LLC ("NEI", and together with NGG, the "NewcoGen Funds"). NG is also the general partner of AGTC Partners, L.P., which is the general partner of AGTC Advisors Fund, L.P. ("AGTCA") and Applied Genomic Technology Capital Fund L.P. ("AGTCF", and together with AGTCA, the "AGTC Funds"). NG is a wholly-owned subsidiary of Flagship Ventures Management, Inc. ("Flagship"). Noubar Afeyan and Edwin M. Kania, Jr. are directors of Flagship and may be deemed to beneficially own the securities held by the NewcoGen Funds and the AGTC Funds. Each of Messrs. Afeyan and Kania disclaim beneficial ownership of the securities except to the extent of his pecuniary interest therein.
  2. On December 3, 2014, NEI exercised a warrant to purchase 12,021 shares of Common Stock for $0.04 per share. NEI exercised the warrant on a cashless basis, resulting in the Issuer's withholding of 927 of the warrant shares to pay the exercise price and issuing to NEI the remaining 11,094 shares.
  3. The price reflects the average of the closing prices of the Common Stock over the five day period prior to the exercise date.
  4. On December 3, 2014, NEI exercised a warrant to purchase 5,988 shares of Common Stock for $0.02 per share. NEI exercised the warrant on a cashless basis, resulting in the Issuer's withholding of 216 of the warrant shares to pay the exercise price and issuing to NEI the remaining 5,772 shares.
  5. On December 3, 2014, NEI exercised a warrant to purchase 12,183 shares of Common Stock for $0.02 per share. NEI exercised the warrant on a cashless basis, resulting in the Issuer's withholding of 440 of the warrant shares to pay the exercise price and issuing to NEI the remaining 11,743 shares.
  6. On December 3, 2014, NEI exercised a warrant to purchase 12,183 shares of Common Stock for $0.02 per share. NEI exercised the warrant on a cashless basis, resulting in the Issuer's withholding of 440 of the warrant shares to pay the exercise price and issuing to NEI the remaining 11,743 shares.
  7. On December 3, 2014, NEI exercised a warrant to purchase 12,183 shares of Common Stock for $0.02 per share. NEI exercised the warrant on a cashless basis, resulting in the Issuer's withholding of 440 of the warrant shares to pay the exercise price and issuing to NEI the remaining 11,743 shares.
  8. In addition to the cashless exercises of the warrants reported above, this Form 4 is being filed to report a pro-rata distribution by NEI for no consideration to its members. As a member of NEI, Mr. Afeyan received 11,190 shares of Common Stock in the distribution.The beneficial ownership of the entities named in this Form 4, other than the Reporting Persons filing this Form 4, did not change as a result of this transaction.
  9. Noubar Afeyan and Edwin M. Kania, Jr. are managers of Flagship Ventures 2007 General Partner, LLC, which is the general partner of Flagship Ventures Fund 2007, L.P., and may be deemed to beneficially own the securities held by Flagship Ventures Fund 2007, L.P. Each of Messrs. Afeyan and Kania disclaim beneficial ownership of the securities except to the extent of his pecuniary interest therein.
  10. This warrant is immediately exercisable.